Karachi: LIVEN Pharma Limited has announced the signing of a Memorandum of Understanding (MOU) with TOFFLON Science and Technology Group Co., Ltd., a Chinese tech giant known for its advanced pharmaceutical and biotechnology manufacturing technologies. The announcement was made on June 24, 2026, marking a significant development for LIVEN Pharma and Pakistan's pharmaceutical sector.
The MOU was executed during an auspicious ceremony in Shanghai, coinciding with the CPHI event, and was signed by Mr. Michael Chang, Senior Vice President of TOFFLON, and Mr. Kaashif Hussain, CEO of LIVEN Pharma Limited. This collaboration reflects a strategic emphasis on establishing a long-term partnership between the two entities, signaling a new era of recognition for LIVEN Pharma and Pakistan in the global pharmaceutical landscape.
According to information available from the Pakistan Stock Exchange (PSX), this strategic milestone aligns with LIVEN Pharma Limited's Vision 2030. The company aims to evolve into a fully integrated pharmaceutical and biotechnology enterprise by acquiring advanced manufacturing technologies and enhancing Pakistan's manufacturing infrastructure for high-value pharmaceuticals.
The collaboration is seen as a landmark achievement, with LIVEN Pharma becoming the first Pakistani pharmaceutical company to engage in such a comprehensive framework arrangement with a globally recognized Chinese technology group. This MOU underscores growing international confidence in Pakistan's pharmaceutical industry and LIVEN Pharma's commitment to attracting foreign technology, direct investment, and expertise.
The partnership is expected to advance the company's long-term strategic goals, including the localization of sophisticated manufacturing capabilities, enhancement of export competitiveness, and strengthening of national healthcare infrastructure. It aims to reduce reliance on imported high-value biological products by developing local manufacturing capabilities.
While the MOU establishes a framework for future cooperation, it is not a confirmation of any definitive agreement or capital commitment at this stage. Any further developments will be subject to technical evaluations, commercial negotiations, regulatory and corporate approvals, and the execution of definitive agreements. LIVEN Pharma has committed to keeping the Exchange informed of any material developments in compliance with regulatory requirements.
This announcement is part of the company's efforts to ensure transparency and keep stakeholders informed about ongoing deliberations, highlighting the importance of this strategic collaboration for both LIVEN Pharma and Pakistan's pharmaceutical industry.